A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Nademanee, A
Molina, A
Forman, SJ
Kogut, N
Yamauchi, D
An, L
White, CA
Raubitschek, A
机构：
[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[2] Kaiser Permanente City Hope, Bone Marrow Transplant Program, Duarte, CA 91010 USA
[3] Idec Pharmaceut Corp, San Diego, CA USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
679
引用
收藏
页码：182A / 182A
页数：1
相关论文
共 50 条
  • [1] High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL):: Update of a phase I/II trial.
    Nademanee, A
    Forman, SJ
    Molina, A
    Kogut, N
    Fung, HC
    Yamauchi, D
    Anderson, AL
    Smith, D
    Liu, AN
    Raubitschek, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 559S - 559S
  • [2] Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-Cell non-hodgkin's lymphoma.
    Nademanee, Auayporn
    Raubitschek, Andrew
    Molina, Arturo
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Krishnan, Amrita
    Kogut, Neil
    Forman, Stephen
    BLOOD, 2007, 110 (11) : 560A - 560A
  • [3] A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
    Nademanee, A
    Forman, S
    Molina, A
    Fung, H
    Smith, D
    Dagis, A
    Kwok, C
    Yamauchi, D
    Anderson, AL
    Falk, P
    Krishnan, A
    Kirschbaum, M
    Kogut, N
    Nakamura, R
    O'Donnell, M
    Parker, P
    Popplewell, L
    Pullarkat, V
    Rodriguez, R
    Sahebi, F
    Smith, E
    Snyder, D
    Stein, A
    Spielberger, R
    Zain, J
    White, C
    Raubitschek, A
    BLOOD, 2005, 106 (08) : 2896 - 2902
  • [4] Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT).
    Vose, JM
    Bierman, PJ
    Lynch, JC
    Bociek, GR
    Multani, PS
    Armitage, JO
    BLOOD, 2003, 102 (11) : 30A - 30A
  • [5] Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphoma
    Juliusson, G
    Liliemark, J
    ANNALS OF ONCOLOGY, 1996, 7 (10) : 1037 - 1041
  • [6] A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)
    Dispenzieri, Angela
    Gertz, Morie Abraham
    Lacy, Martha Q.
    Laumann, Kristina
    LaPlant, Betsy R.
    Kumar, Shaji
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Hogan, William J.
    Ansell, Stephen M.
    Gastineau, Dennis A.
    Inwards, David James
    Micallef, Ivana N.
    Porrata, Luis F.
    Johnston, Patrick B.
    Litzow, Mark R.
    Witzig, Thomas E.
    BLOOD, 2011, 118 (21) : 1337 - 1338
  • [7] Pulmonary mortality after high-dose oral busulfan and autologous stem cell transplant (ASCT) in patients with non-Hodgkin lymphoma (NHL).
    Kalaycio, M
    Pohlman, B
    Rybicki, L
    Sobecks, R
    Kuczkowski, E
    Andresen, S
    Brown, S
    Bolwell, B
    BLOOD, 2005, 106 (11) : 501A - 502A
  • [8] A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma
    Srivastava, Shivani
    Jones, David
    Wood, Lisa L.
    Schwartz, Jennifer E.
    Nelson, Robert P., Jr.
    Abonour, Rafat
    Secrest, Angie
    Cox, Elizabeth
    Baute, Jay
    Sullivan, Cheryl
    Kane, Kathleen
    Robertson, Michael.
    Farag, Sherif S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (07) : 987 - 994
  • [9] High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma
    Rossi, HA
    Becker, PS
    Emmons, RVB
    Westervelt, P
    Levy, W
    Liu, Q
    Clark, Y
    Ballen, K
    BONE MARROW TRANSPLANTATION, 2003, 31 (06) : 441 - 446
  • [10] High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma
    H A Rossi
    P S Becker
    R V B Emmons
    P Westervelt
    W Levy
    Q Liu
    Y Clark
    K Ballen
    Bone Marrow Transplantation, 2003, 31 : 441 - 446
12345